| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3787 | nsc-681152 | Novel inhibitor of the Skp2-Cks1 protein-protein interaction and p27(Kip1) ubiquitination in vitro |
|
| DCC3788 | Nsc-689857 | Novel inhibitor of the Skp2-Cks1 protein-protein interaction and p27Kip1 ubiquitination in vitro |
|
| DCC3789 | Nsc704342 | Novel Inhibitor of HCV NS3/4A Proteinase |
|
| DCC3790 | Nsc705841 | Novel selective serotonin reuptake inhibitor (SSRI), exhibiting higher binding affinities in comparison with the paroxetine |
|
| DCC3791 | Nsc724526 | Novel Inhibitor of HCV NS3/4A Proteinase |
|
| DCC3792 | Nsc724527 | Novel Inhibitor of HCV NS3/4A Proteinase |
|
| DCC3793 | Nsc-73306 | Cytotoxic MDR-selective ligand |
|
| DCC3794 | Nsc-741909 | Novel anticancer agent, suppressing the growth of several cell lines derived from lung, colon, breast, ovarian, and kidney cancers |
|
| DCC3795 | Nsc745885 | Novel down-regulator of EZH2, inducing G2/M cell-cycle arrest of cancer cells and degradating p53 via proteasome-dependent and -independent pathways |
|
| DCC3796 | nsc746364 | Telomerase inhibitor, stabilizing G-quadruplex and suppressing cell growth of A549 human lung cancer cells through activation of the ATR/Chk1-dependent pathway |
|
| DCC3797 | nsc746365 Maleate | Telomerase inhibitor, anticancer agent |
|
| DCC3798 | Nsc747854 | Novel inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1) |
|
| DCC3799 | Nsc750212 | Novel inhibitor of lipid metabolism, disrupting tubulin polymerization,suppressing monoglycerol metabolism depleting lipids and inhibiting the growth of both lymphoma and RCC both in vitro and in vivo |
|
| DCC3800 | Nsc-77053 | The first reported BoNT/E small molecule inhibitor |
|
| DCC3801 | Nsc-79887 | Novel inhibitor of nucleoside hydrolase (NH) |
|
| DCC3802 | Nsc-80141 | Selective inhibitor of HsEg5 |
|
| DCC3803 | Nsc-84096 | Potent inhibitor of endopeptidase activity of botulinum neurotoxin type A light chain (rBoNT/A-LC) |
|
| DCC3804 | Nsc-8891 | Tyrosyl-DNA phosphodiesterase (Tdp1) inhibitor |
|
| DCC3805 | Nsc-9037 | First-in-class probe of Rad6 function, inhibiting Rad6 function and Rad6-Rad18 interaction in the PCNA ubiquitination cascade |
|
| DCC3806 | nsc-96626 | Novel B-Raf(V600E) inhibitor |
|
| DCC3807 | Nsi-189 Phosphate | Novel stimulator of neurogenesis of human hippocampus-derived neural stem cells in vitro and in vivo. |
|
| DCC3808 | Nsmase2-in-1 | Novel inhibitor of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases |
|
| DCC3809 | Nsp-116 | Novel free radical scavenger, against light-induced photoreceptor cell damage |
|
| DCC3810 | Nti-007 | Potent anti-HBV agent, targeting the NTCP-APOA1-HBx-Beclin1-mediated autophagic pathway |
|
| DCC3811 | Ntrc-739 | Novel nonpeptide selective ligand for NTS2 |
|
| DCC3812 | Ntrc-808 | Novel nonpeptide potent and selective partial agonist of the Neurotensin receptor type 2 (NTS2) |
|
| DCC3813 | Ntrd22 | Novel Allosteric Modulator of RNA Binding Targeting the N-Terminal Domain of TDP-43 |
|
| DCC3814 | Ntr-responsive Protac 17-1 | The first NTR-responsive PROTAC, incorporating the caging group on the Von Hippel-Lindau (VHL) E3 ubiquitin ligase ligand, efficiently degrading the EGFR protein and subsequently exert antitumor efficacy |
|
| DCC3815 | Ntz-15 | Novel potent STAT3 inhibitor, exhibiting much improved in vivo pharmacokinetic parameters in rats and efficacies against proliferations in multiple cancer cell lines |
|
| DCC3816 | Ntz-24 | Novel potent STAT3 inhibitor |
|
